The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.
 
Sidra Khalid
No Relationships to Disclose
 
Bassam Mohammed Basulaiman
No Relationships to Disclose
 
Jeff Emack
No Relationships to Disclose
 
Christopher M. Booth
No Relationships to Disclose
 
David Hernandez-Barajas
No Relationships to Disclose
 
Ignacio Duran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech
 
Martin Smoragiewicz
No Relationships to Disclose
 
Eitan Amir
Honoraria - Agendia; Apobiologix; Myriad Genetics
Expert Testimony - Genentech/Roche
 
Francisco Vera-Badillo
No Relationships to Disclose